
ADMA Biologics Inc: updates and filings
Price
$13.56
November 18, 2026Market cap $3.0B
What Ploutos Investor adds for ADMA Biologics
Part of Ploutos Investor, €9.99 a month
- The full history: 15 fiscal years, from 2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 30% since Nov 4, 2026, when the 10-Q these figures come from was filed ($10.48 then, $13.61 on Nov 18, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operationsForm8-K
- Jun 2, 2026Shareholder voteForm8-K
- May 6, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- May 4, 2026Other material eventsForm8-K
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 15, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 15, 2026Additional annual meeting materialFormDEFA14A
- Apr 15, 2026Annual meeting proxy statementFormDEF 14A
- Mar 27, 2026Regulation FD disclosureForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 2, 2026Regulation FD disclosure, other material eventsForm8-K
- Feb 25, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 25, 2026Results of operations, officer or director changeForm8-K
- Feb 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jan 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Nov 5, 2025Quarterly reportfor the period to Sep 30, 2025Form10-Q
- Nov 5, 2025Results of operationsForm8-K
- Sep 29, 2025Letter from the SECFormUPLOAD
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Jun 2, 2026 | 8-K | Shareholder vote | Document |
| May 6, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| May 4, 2026 | 8-K | Other material events | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 15, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 15, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 15, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 27, 2026 | 8-K | Regulation FD disclosure | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 2, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Feb 25, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 25, 2026 | 8-K | Results of operations, officer or director change | Document |
| Feb 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jan 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Nov 5, 2025 | 10-Q | Quarterly reportfor the period to Sep 30, 2025 | Document |
| Nov 5, 2025 | 8-K | Results of operations | Document |
| Sep 29, 2025 | UPLOAD | Letter from the SEC | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jul 10, 2006.
The full analysis
What do ADMA Biologics's filings show?
The filings are where every one of ADMA Biologics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.